YS Biopharma Announces Changes to its Board Committees - Jan 08, 2024

2024-01-08

高管变更疫苗

GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company's Board of Directors (the "Board") has approved Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee on January 7, 2024 (Beijing Time), with immediate effect. Ms. Yu currently serves as a partner at Oceanpine Capital, a position she has held since 2021. Prior to that, she served as a managing director at China Renaissance Group and vice president and head of China healthcare research at Gerson Lehman Group. Ms. Yu received her Bachelor of Science degree from Guangdong Pharmaceutical University, her Master of Science degree from the University of Missouri School of Medicine, and her MBA from the University of Chicago Booth School of Business with concentrations in finance, accounting and entrepreneurship. Accordingly, the membership of each Board Committee will be as follows: Audit Committee Rui Yu (Chairperson), Viren Mehta, and Shaojing Tong Compensation Committee Viren Mehta (Chairperson), Ajit Shetty, Shaojing Tong, and Rui Yu Nominating and Corporate Governance Committee Ajit Shetty (Chairperson), Viren Mehta, Rui Yu, and Yi Zhang About YS Biopharma YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit investor.ysbiopharm.com. Investor Relations Contact Robin Yang Partner, ICR, LLC Tel: +1 (212) 537-4035 Email: YSBiopharma.IR@icrinc.com View original content to download multimedia: SOURCE YS Biopharma Co., Ltd. Company Codes: NASDAQ-NMS:YS

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

YS Biopharma Co. Ltd.